| David J Walsh, MD | |
|
171 Ashley Ave, Charleston, SC 29425-8908 | |
| (843) 792-6200 | |
| Not Available |
| Full Name | David J Walsh |
|---|---|
| Gender | Male |
| Speciality | Psychiatry & Neurology - Neurology |
| Location | 171 Ashley Ave, Charleston, South Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053337907 | NPI | - | NPPES |
| Entity Name | University Medical Associates Of The Medical University Of South Carol |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043241110 PECOS PAC ID: 6305758574 Enrollment ID: O20031105000291 |
News Archive
Brown fat is something that occurs more in thin people than fat, younger people than older and young women than men. It is brown in color and a new study finds that one form of it, which is turned on in cold climates can burn calories from elsewhere in the body to keep the body warm. Another new study finds that a second form of brown fat can be created from ordinary white fat by exercise.
Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).
Distinguished Professor Jae Jung, PhD, chair of the Department of Molecular Microbiology & Immunology and the director of the University of Southern California Institute for Emerging Pathogens and Immune Diseases at the Keck School of Medicine of USC, is among this year's recipients of the National Cancer Institute Outstanding Investigator Award.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
› Verified 4 days ago
| Entity Name | Georgetown Memorial Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982604021 PECOS PAC ID: 8224942123 Enrollment ID: O20031114000600 |
News Archive
Brown fat is something that occurs more in thin people than fat, younger people than older and young women than men. It is brown in color and a new study finds that one form of it, which is turned on in cold climates can burn calories from elsewhere in the body to keep the body warm. Another new study finds that a second form of brown fat can be created from ordinary white fat by exercise.
Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).
Distinguished Professor Jae Jung, PhD, chair of the Department of Molecular Microbiology & Immunology and the director of the University of Southern California Institute for Emerging Pathogens and Immune Diseases at the Keck School of Medicine of USC, is among this year's recipients of the National Cancer Institute Outstanding Investigator Award.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
› Verified 4 days ago
| Entity Name | Waccamaw Community Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1972503910 PECOS PAC ID: 9133036932 Enrollment ID: O20031126000386 |
News Archive
Brown fat is something that occurs more in thin people than fat, younger people than older and young women than men. It is brown in color and a new study finds that one form of it, which is turned on in cold climates can burn calories from elsewhere in the body to keep the body warm. Another new study finds that a second form of brown fat can be created from ordinary white fat by exercise.
Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).
Distinguished Professor Jae Jung, PhD, chair of the Department of Molecular Microbiology & Immunology and the director of the University of Southern California Institute for Emerging Pathogens and Immune Diseases at the Keck School of Medicine of USC, is among this year's recipients of the National Cancer Institute Outstanding Investigator Award.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
› Verified 4 days ago
| Entity Name | The Regional Medical Center Of Orangeburg And Calhoun Counties |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922063858 PECOS PAC ID: 8527970771 Enrollment ID: O20040112000062 |
News Archive
Brown fat is something that occurs more in thin people than fat, younger people than older and young women than men. It is brown in color and a new study finds that one form of it, which is turned on in cold climates can burn calories from elsewhere in the body to keep the body warm. Another new study finds that a second form of brown fat can be created from ordinary white fat by exercise.
Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).
Distinguished Professor Jae Jung, PhD, chair of the Department of Molecular Microbiology & Immunology and the director of the University of Southern California Institute for Emerging Pathogens and Immune Diseases at the Keck School of Medicine of USC, is among this year's recipients of the National Cancer Institute Outstanding Investigator Award.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| David J Walsh, MD Po Box 751461, Charlotte, NC 28275-1461 Ph: (843) 792-6200 | David J Walsh, MD 171 Ashley Ave, Charleston, SC 29425-8908 Ph: (843) 792-6200 |
News Archive
Brown fat is something that occurs more in thin people than fat, younger people than older and young women than men. It is brown in color and a new study finds that one form of it, which is turned on in cold climates can burn calories from elsewhere in the body to keep the body warm. Another new study finds that a second form of brown fat can be created from ordinary white fat by exercise.
Inspire Medical Systems, a leading developer of neuro-stimulation therapies for the treatment of obstructive sleep apnea (OSA), announced today that the company has received approval from the U.S. Food and Drug Administration (FDA) to begin its STAR pivotal clinical trial. The STAR trial (Stimulation Therapy for Apnea Reduction), is a multi-center study that will evaluate both the safety and effectiveness of Inspire Upper Airway Stimulation (UAS) therapy in patients with moderate to severe obstructive sleep apnea (OSA).
Distinguished Professor Jae Jung, PhD, chair of the Department of Molecular Microbiology & Immunology and the director of the University of Southern California Institute for Emerging Pathogens and Immune Diseases at the Keck School of Medicine of USC, is among this year's recipients of the National Cancer Institute Outstanding Investigator Award.
Aimmune Therapeutics, Inc., a privately held biopharmaceutical company developing desensitization treatments for food allergies, announced today that a Phase 2 study (ARC001) evaluating the company's lead investigational product, AR101 for the treatment of peanut allergy, met its primary endpoint and additional endpoint of desensitizing patients to cumulative amounts of peanut protein of 443 mg and 1,043 mg, respectively.
› Verified 4 days ago
Christine Lloyd, MD Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 198 Rutledge Ave, Charleston, SC 29403 Phone: 843-577-5012 Fax: 843-722-8368 | |
Robert Joseph Adams, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 Fax: 843-792-2484 | |
Kevin Michael Gray, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Melanie Anne Lobel, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 171 Ashley Ave, Charleston, SC 29425 Phone: 843-792-1414 | |
Billy Beck, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 109 Bee St, Charleston, SC 29401 Phone: 843-577-5011 | |
Ciara Monet Styles, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 67 President St, Charleston, SC 29425 Phone: 843-792-9888 | |
Alexandra Goslow, MD Psychiatry & Neurology Medicare: Medicare Enrolled Practice Location: 67 President St, Charleston, SC 29425 Phone: 843-792-9888 |